Skip directly to content

Improving Patient Care in Tobacco Dependency

The 2019 Improving Patient Care in Tobacco Dependency (IPCTD) Programme aims to improve patient care through enhanced provision of stop smoking support and will be open to accepting applications between 01 May–30 June 2019.

 

Applications are invited from Foundation Trusts, Clinical Commissioning Groups (CCGs), General Practice (GP) Federations and other healthcare organisations that provide or wish to provide Stop Smoking Support. Unfortunately, we cannot accept applications from individual GP practices.

 

We are particularly interested in receiving proposals / innovative pilots that fulfil any of the following criteria:

  • Enhance or establish patient access to tobacco dependency support in general practice and secondary care through innovative approaches.
  • Provide an educational legacy to support continued management of tobacco dependency.

 

Please note that applications must be in line with national guidance for smoking cessation/tobacco dependency.

Proposals for projects covering the following areas are out of scope of this call:

  • Projects bearing the name or class of specific medicines
  • Projects designed to increase the uptake of a single therapeutic agent or intervention (projects should be aimed at improving adherence to specific guidelines or patient pathways)
  • Projects that are in scope of one of Pfizer’s other Smoking Cessation MEGS programmes
    > Quit @ Work
    > Enhance in Practice
  • Applications for funding of services which should be provided as standard within the NHS
  • Interventional or observational clinical studies
  • In vitro or in vivo (animal) studies
  • Non-interventional studies, such as epidemiological studies
  • Outcomes research studies where the primary focus is to understand the results of particular healthcare practices and interventions as well as to monitor and improve the quality of care
  • Other types of independent research on disease states, including novel diagnostic screening tools and surveys

 

Please click here for further information and apply for Improving Patient Care in Tobacco Dependency MEGS.

The deadline for submission is 30 June 2019 and applications will be reviewed in July 2019 to evaluate and select the best proposals.

Pfizer UK is processing these applications through the Pfizer Global Medical Grants System which enables the review and consideration of an individual grant request submissions from a healthcare organisation which is intended to support an independent medical and/or scientific initiative of that healthcare organisation intended for quality improvement and to improve patient outcomes, in an area of unmet medical need that is aligned with Pfizer’s medical and/or scientific strategies.

A Quality Improvement Grant is a type of grant that supports independent quality improvement projects for systematic and continuous actions, that lead to measurable improvements in healthcare services and the health status of individuals and targets patient groups, aimed to improve patient outcomes in areas of unmet medical need that do not relate to a Pfizer asset but that are aligned with Pfizer’s medical and/or scientific strategies (e.g., aspects of quality such as clinical competence, outcomes and process assessment, program evaluation, quality indicators, and quality assurance using methodologically rigorous protocols with an endpoint goal of readiness for application to practice).

For all independent grants, the grant requester and the healthcare organisation grantee is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the initiative.

If you would like to submit an application, please do so via the Pfizer online Global Medical Grants System portal. IPCTD is an example of a Quality Improvement Grant application.

Note: First time users will need to use their Healthcare Organisation / NHS email address and Create a password.

If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the log in webpage.

To contact Pfizer for any other purpose, including adverse event reports, medical information requests, or data protection enquiries please call 01304 616161.

PP-GIP-GBR-4271 / April 2019